GE HealthCare Technologies Inc. (GEHC)
(Delayed Data from NSDQ)
$78.75 USD
-1.10 (-1.38%)
Updated May 28, 2024 04:00 PM ET
After-Market: $78.76 +0.01 (0.01%) 6:20 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
GEHC 78.75 -1.10(-1.38%)
Will GEHC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GEHC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GEHC
GE HealthCare Technologies Inc. (GEHC) is Attracting Investor Attention: Here is What You Should Know
GE HealthCare (GEHC), Medis Medical Partner to Aid CAD Therapy
GEHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
GE HealthCare Technologies Inc. (GEHC) Is a Trending Stock: Facts to Know Before Betting on It
GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
Other News for GEHC
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for May 2024
Spinoff Speed Demons: How Much Further Can These 3 Stocks Run?
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
GE HealthCare Tops List for Third Year in a Row with Highest Number of AI-Enabled Medical Device Authorizations
Citi upgrades Edwards, Tandem; cuts Nevro, Establishment Labs